From the Journals

DOACs’ safety affirmed in real-world setting

Publish date: July 9, 2018

 

FROM THE BMJ

The study was supported by a grant from the National Institute for Health Research. The investigators had no relevant disclosures.

SOURCE: Vinogradova Y et al. BMJ 2018; 362:K2505.

Pages

Recommended Reading

DOAC’s edge over warfarin fades with low adherence
MDedge Hematology and Oncology
RBC transfusions with surgery may increase VTE risk
MDedge Hematology and Oncology
Low vitamin D linked with DVT in lupus patients
MDedge Hematology and Oncology
New look at ATLAS suggests rivaroxaban may still have role in ACS
MDedge Hematology and Oncology
Lower risk of bleeding with apixaban
MDedge Hematology and Oncology
CHMP recommends rVWF for VWD
MDedge Hematology and Oncology
CHMP backs approval of caplacizumab
MDedge Hematology and Oncology
Perioperative RBC transfusions linked to VTE
MDedge Hematology and Oncology
Survey reveals patient perceptions of ITP
MDedge Hematology and Oncology
Drug is convenient alternative for PNH, doc says
MDedge Hematology and Oncology